Biocon and Handok link to commercialise Liraglutide in South Korea
License out/inDrug Approval
Preview
Source: Pharmaceutical Technology
Biocon will handle Liraglutide’s development, manufacturing and supply. Credit: Poetra.RH / Shutterstock.com.
Indian biopharmaceutical company Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.
A vertically integrated, complex drug, Liraglutide is administered using pre-filled injection pens. It is designed for chronic weight management alongside a reduced-calorie diet and increased physical activity.
Biocon will handle Liraglutide’s development, manufacture and supply in South Korea.
Handok will oversee the regulatory approvals and commercialisation of the product in the market.
Preview
Source: Pharmaceutical Technology
(Cilostazol + rosuvastatin) by Korea United Pharm for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Global contract research organisation IQVIA‘s moving annual total for the fourth quarter of 2023 values the market opportunity for Liraglutide in South Korea at $47m.
Biocon CEO and MD Siddharth Mittal stated: “We are pleased to enter into this strategic partnership with Handok, which will enable patients in South Korea dealing with weight management to gain access to our GLP-1 peptide drug product, synthetic Liraglutide.
“This also aligns with our commitment to expand our portfolio of innovative, affordable medicines to address the unmet needs of patients around the world. We look forward to leveraging Handok’s strong capabilities to help patients in the region better manage their disease.”
In December 2023, Biocon’s subsidiary Biocon Biologics completed the integration of Viatris’ biosimilars business across 31 European countries.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.